Improving Health Outcomes With Kefir
Condition(s) studied
Investigational drug(s) / intervention(s)
Traditional Kefir: 350 mL/day of traditional fermented/prepared kefir
Milk (placebo): 350 mL/day of commercial 2% fat milk
Study summary
The purpose of the study is to ascertain whether traditional kefir not only enhances vascular health but also contributes to improved immune outcomes in both male and female participants at higher risk or living with Type 2 Diabetes (T2D) after 12 weeks of treatment.
Eligibility
Primary outcome measure(s)
- Change in Glycated Hemoglobin (HbA1c) Levels (Percentage) — Baseline, 6 weeks, 12 weeks
The primary outcome is the change in HbA1c levels, measured as a percentage of total hemoglobin using standard laboratory methods. This measurement assesses average blood glucose levels over the past 2-3 months, providing insight into the effect of our traditional kefir on long-term glucose regulation.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| University of Alberta | Edmonton | Alberta | Recruiting |
More University of Alberta trials in Canada
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06695221 on ClinicalTrials.gov ↗ ← All trials in Canada